The mission of the cardiovascular pharmacogenomics and Precision medicine is to train graduate students and researchers on performing pharmacogenomics studies including different genotyping techniques and the clinical applications of genetics especially in the field of cardiovascular disease.

Since 2014, our lab has secured over 1 million Qatari Rial for clinical and translational research projects that focus on the applications of pharmacogenomics especially in the field of cardiovascular disease. Our research projects helped define the impact of genetics on warfarin dosing, clopidogrel efficacy and safety in Arabs and more specifically in the Qatari population. Pharmacogenomics and precision medicine lab also published the first Genome Wide Association study (GWAS) on warfarin dosing in the MENA region. Our ultimate goal is to spread the knowledge on the applications of genetics in the healthcare system and to launch a pharmacist-led pharmacogenetic service at Hamad Medical Corporation, the main care provider facility in Qatar. Aside from genomics, our group has conducted multiple clinical research studies in the area of cardiology and anticoagulation.

Our ultimate goal is to spread the knowledge on the applications of genetics in the healthcare system and to launch a pharmacist-led pharmacogenetic service at Hamad Medical Corporation, the main care provider facility in Qatar. Aside from genomics, our group has conducted multiple clinical research studies in the area of cardiology and anticoagulation.